Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX) is a healthcare company (biotechnology) based in the United States. The share price is $533.13, down 0.87% on the day, which values the company at $135.17B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.

Key facts

Share price
$533.13−0.87% today
Market value
$135.17B
P/E ratio
34.3×last 12 months
Forward P/E
26.8×
Funk Score
69/100
Against its own history
About its usual priceusual price $511.97
200-week average
$429.4724% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Vertex Pharmaceuticals Incorporated in more detail

VRTX trades at 34.3× its last twelve months' earnings, 26.8× next year's expected earnings, 10.4× sales. Measured against its own history, the price is 4% above what its usual multiples would imply ($511.97) — about its usual price. It sits 24% above its 200-week average of $429.47.

Over the last five fiscal years Vertex Pharmaceuticals Incorporated has compounded revenue 14.1% a year, earnings per share 8.3% a year, free cash flow 1.3% a year. Its Funk Score is 69 out of 100 (financial strength 9.3, profitability 8.8, growth 5.9, value 3.6, each out of 10).

In its favour: Altman Z in the safe zone; Five straight years of revenue growth.

5 of the superinvestors tracked here hold VRTX, including Tweedy, Browne team (1.1% of the portfolio), Jim Simons (1938–2024) (0.3% of the portfolio), Israel Englander (0.2% of the portfolio).

Superinvestors holding VRTX

5 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:VRTX vs MDT (Vertex Pharmaceuticals Incorporated vs Medtronic)VRTX vs BMY (Vertex Pharmaceuticals Incorporated vs Bristol-Myers Squibb)VRTX vs ISRG (Vertex Pharmaceuticals Incorporated vs Intuitive Surgical)VRTX vs DHR (Vertex Pharmaceuticals Incorporated vs Danaher)VRTX vs PFE (Vertex Pharmaceuticals Incorporated vs Pfizer)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Vertex Pharmaceuticals Incorporated (VRTX): questions and answers

What is VRTX's P/E ratio?

Vertex Pharmaceuticals Incorporated trades at 34.3× its last twelve months' earnings and 26.8× next year's expected earnings. At its fiscal year-ends over the past 9 years the P/E ranged from 20.5× to 237.2×, with a median of 29.3×.

What is VRTX's PEG ratio?

Vertex Pharmaceuticals Incorporated's PEG ratio is 2.34 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Vertex Pharmaceuticals Incorporated's market cap?

Vertex Pharmaceuticals Incorporated is valued at $135.17B at a share price of $533.13.

Is VRTX overvalued or undervalued?

Against its own history, VRTX is about its usual price: the price is 4% above the $511.97 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is VRTX above its 200-week moving average?

Yes. VRTX is 24.1% above its 200-week average of $429.47. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Vertex Pharmaceuticals Incorporated growing?

Over the last five fiscal years Vertex Pharmaceuticals Incorporated's revenue grew 14.1% a year and its earnings per share 8.3% a year; over ten years revenue grew 27.8% a year.

Cite this page

Funkfolio, “Vertex Pharmaceuticals Incorporated (VRTX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/VRTX

Underlying data: Yahoo Finance; company filings with the SEC.